Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

solution of DOTA tri-t-butyl ester (0.972 g, 1.70 mmol), HBTU (0.772 g, 2.04 mmol), HOBt (0.312 g, 2.04 mmol), and DIEA (0.59 niL, 5.9 mmol) in anhydrous DMF (8.0 mL) was stirred at room temperature under nitrogen for 20 minutes. The product of Part B (1.38 g, 1.70 mmol) was added in one portion. Additional HBTU (0.772 g, 2.04 mmol) was added after 1 hour and the reaction was stirred for an additional 3 hours. The reaction mixture was quenched with 10% citric acid (20 mL) and diluted with dichloromethane (30 mL). The aqueous layer was extracted with dichloromethane (3 x 30 mL). The combined organic extracts were washed consecutively with 10% citric acid (30 mL), saturated NaHCO3 (3 x 30 mL), and saturated NaCl (3 x 30 mL), dried (MgSO4), filtered, and concentrated to give a yellow oil. The oil was purified by flash chromatography over silica gel, eluting with ethyl acetate to give the title compound as a colorless oil (0.746 g, 48%). 1H NMR (4:1 CDCl3:DMSO-<4): delta 7.54 (m, 2H), 7.41 (m, 2H), 7.17 (m, 2H), 7.08 (m, 2H), 4.15 (d, 2H), 4.02 (m, IH), 2.97 (m, 2H), 2.68-2.45 (m, 24H), 2.00 (t, 2H), 1.44 (t, 2H), 1.30-1.11 (m, 31H). MS (ESI): 461.9 (100, M+2H), 922.5 (80, M+H)., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103505-54-0, [2,2′-Bipyridine]-6,6′(1H,1’H)-dione is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

As shown in Synthesis Scheme 1-a, to a dicationic Cp * iridium-aco complex (407.8 mg, 0.60 mmol) was added 6,6′-dihydroxy-2,2′-bipyridine ligand (113.8 mg, 0 , 60 mmol) was allowed to act in an aqueous solvent (12 mL) to obtain a complex A (yield 93%). Subsequently, neutral iridium complex 1 was obtained by allowing sodium t-butoxide (211.4 mg, 2.2 mmol) to react with complex A (915.0 mg, 1.1 mmol) in an aqueous solvent (30 mL) (Yield 84%)., 103505-54-0

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; KANTO CHEM CO INC; YAMAGUCHI, RYOHEI; FUJITA, KENICHI; (38 pag.)JP2015/83544; (2015); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7: 1-r(3-(6-Methyl-4-r(3.3.3-trifluoro-2-m(4-fluorophenvnsulfonylU1- methylethv?aminolmethyl’y-2-hvdroxypropy?aminol-1/-/-indazol-1-yl)phenv?carbonyl1- D-prolinamide; lambda/,lambda/-Diisopropylethylamine (0.0644mL) and HATU (29.5mg) were added to a solution of 3-(4-{[2-({ethyl[(4-fluorophenyl)sulfonyl]amino}methyl)-3,3,3-trifluoro-2- hydroxypropyl]amino}-6-methyl-1/-/-indazol-1-yl)benzoic acid (45mg, 0.074mmol) in DMF (1.4mL) and the mixture stirred at room temperature under for 10 min. D- Prolinamide (21.1 mg) was then added and the mixture stirred at room temperature overnight. More D-prolinamide was added and the mixture stirred for a further 24 hours and then diluted slightly with methanol and purified by mass directed autopreparation (System B). Product containing fractions were combined and partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The aqueous phase was re-extracted with dichloromethane and the combined organic extracts were washed successively with water and brine, dried through a hydrophobic frit and evaporated to give the title compound (22.2mg). LCMS: tRET = 3.38 min; MH+ = 70519mg of this mixture of diastereomers was resolved by chiral HPLC on a 2 x 25cm Chiralpak AD column eluted with heptane : iso-propanol 1 : 1 with a flow rate of 15 mL/min to provide Example 7-A (diastereomer A, 6.5mg) and Example 7-B (diastereomer B, 7.5mg).Example 7-A (diastereomer A): Analytical chiral HPLC (25 x 0.46 cm Chiralpak AD column, heptane : iso-propanol 1 : 1 eluting at 1 mL/min): tREtau = 8.6 min LCMS: tRET = 3.41 min; MH+ = 705Example 7-B (diastereomer B): Analytical chiral HPLC (25 x 0.46 cm Chiralpak AD column, heptane : iso-propanol 1 : 1 eluting at 1 mL/min): tREtau = 11.6 min LCMS: tRET = 3.59 min; MH+ = 705, 62937-45-5

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2009/50218; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

0.592 g (2.79 mmol) of (S,S)-DPEN (MW: 212.3) was introduced into a 50-mL three-necked flask and subjected to argon-gas replacement. 25 mL of dehydrated methylene chloride and 0.41 mL (2.93 mmol) of triethylamine were added and cooled to 0 C. To this solution, a solution consisting of 0.515 g (2.79 mmol) of isohexyl sulfonyl chloride (MW: 184.68) and 25 mL of dehydrated methylene chloride was slowly added dropwise, and stirred at 0 C. for one night. This solution was washed twice with water, then the solvent in the organic layer was distilled away, and dried under reduced pressure to give 1.656 g of a crude product. The crude product was purified by silica-gel column chromatography (silica gel 60N, n-hexane:AcOEt=1:1, then AcOEt 100%) to give 0.306 g of (S,S)-(C2H5)2CHCH2SO2DPEN (30% yield). 1H NMR (400 MHz, CDCl3, rt, delta/ppm): 0.67 (q, J=7.3 Hz, 6H, (C3CH2)2CH), 1.10-1.38 (m, 4H, (CH3C2)2CH), 1.62-1.76 (m, 1H, (CH3CH2)2C), 2.22 (d, J=6.4 Hz, 2H, C2SO2), 4.29 (d, J=5.5 Hz, 1H, C6H5CNH2), 4.56 (d, J=5.5 Hz, 1H, C6H5CNHSO2), 7.15-7.45 (m, 10H, aromatic proton).

29841-69-8, 29841-69-8 (1S,2S)-(-)-1,2-Diphenylethylenediamine 6931238, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; US2010/261924; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Example: Zetaeta(NuO3) 2 ¡¤ 6H20 (29.7 mg, 0.1 mmol), 2,2′-biquinoline (25.6 mg, 0.1 mmol), 2,2 -biphenyl diacid (24.0 mg, 0.1 mmol) and NaN3 (13.2 mg, 0.2 mmol), were added to a mixed solvent of 12 mL methanol and secondary deionized water (1:1 volume ratio), It was sealed in a 25 mL stainless steel container lined with tetrafluoroethylene, heated to 140 C for 3 days, and then slowly cooled to room temperature. After filtration, the filter cake was washed with diethyl ether and dried in air to obtain colorless massive crystals, the calculated yield based on Zn(N03)2¡¤6H20 was approximately 61%. This material was insoluble in water and other organic solvents.

119-91-5, As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Patent; Anqing Teachers College; Xu Heng; Yan Da; Feng Xuejun; Chen Zhengxiang; Xiong Zhi; Huang Rongyi; (9 pag.)CN108017661; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29841-69-8,(1S,2S)-(-)-1,2-Diphenylethylenediamine,as a common compound, the synthetic route is as follows.

To a solution of (S,S)-1,2-diphenylethane-1,2-diamine (424 mg,2 mmol) and triethylamine (280 muL, 2 mmol) in CH2Cl2 (10 mL), 4-(bromomethyl)phenylsulfonyl chloride 1 (525 mg, 1.96 mmol) in dichloromethane(10 mL) were added dropwise at 0 C. The reactionmixture was stirred at room temperature for 0.5 h. After removal ofsolvents under reduced pressure, the residue was purified by silica gelcolumn chromatography. The product 3 was obtained as white solid(0.45 g, 60%). 1H NMR (400 MHz, CDCl3) delta 7.46-7.31 (m, 2H),7.27-6.98 (m, 12H), 4.50 (s, 2H), 4.45 (d, J=5.1 Hz, 1H), 4.20 (d,J=5.2 Hz, 1H). 13C NMR (100 MHz, CDCl3) delta 141.5, 140.0, 136.9,129.0, 128.6, 128.3, 128.2, 127.7, 127.5, 127.5, 127.4, 63.0, 60.0,31.7. HRMS (ESI): m/z calculated for C21H21N2O2SBr [M+H]+:445.0580; found: 445.0583., 29841-69-8

29841-69-8 (1S,2S)-(-)-1,2-Diphenylethylenediamine 6931238, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Zheng, Dongsong; Liu, Rui; Wang, Yu; Cheng, Tanyu; Liu, Guohua; Molecular catalysis; vol. 455; (2018); p. 103 – 107;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2390-68-3,N-Decyl-N,N-dimethyldecan-1-aminium bromide,as a common compound, the synthetic route is as follows.,2390-68-3

Didecyldimethylammonium bromide (0.005 mol) was dissolved 100 mL of 95% ethanol by gentle stirring. Docusate sodium was dissolved in 50 mL of 95% ethanol by gentle stirring. The two solutions were combined and the reaction mixture was stirred for 1 hour at room temperature. A rotary evaporator removed the ethanol to give the ionic liquid and NaBr. The ionic liquid was dissolved in hexane and the NaBr was filtered off. A rotary evaporator removed the hexane to give a white solid obtained in a 78.00% yield. 1H and 13C NMR (DMSO) were obtained. Melting point (hot plate apparatus)=25-30 C.

The synthetic route of 2390-68-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

To a25 mL round bottom flask was added 157.5 mg(1.219 mmol)TACN (1,4,7-triazacyclononane), 3.4 equivalents of 2-bromoacetamide (565.7 mg, 4.100 mmol), and 12 mL ethanol. 3.5 mL triethylamine was added dropwise over several minutes until the solution turned cloudy and persisted, then the mixture was refluxed for 3 hours. After cooling, the mixture was decanted to remove most of the liquid, then 20 mL of warm80% ethanol/20 % water was added to yield a slightly opaque white solution resembling nonfat milk. The volume was slightly reduced under vacuum on a Schlenk line, then placed in the freezer for 3 days to recrystallize. After allowing white crystals to form, the solvent was removed by decanting and further dried under vacuum on the Schlenk line (90 % yield).ESI-MS: m/z = 301.3 (100 %), 302.3 (20 %) [M + H]+; 323.3 (25 %) [M + Na]+. 500 MHz?H NMR spectrum, D20 + DC1: ppm = 3.96 (s, 6H, amide CH2); 3.44 (s, 12H, ring CH2). 75MHz 13C NMR spectrum, D20: ppm = 173.64 (amide CO), 56.75 (amide CH2), 49.30 (ring CH2).

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK UNIVERSITY AT BUFFALO; HEALTH RESEARCH, INC.; MORROW, Janet, R.; TSITOVICH, Pavel, B.; DORAZIO, Sarina, J.; OLATUNDE, Abiola, O.; SNYDER, Eric, M.; SPERNYAK, Joseph, A.; BURNS, Patrick; BOND, Christopher, J.; WO2015/38943; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Bis-aldehyde c (0.53 g,1.1 mmol) in dry THF (1.2 mL) was taken in a single-necked 50 mL round-bottom flask to which the solution of 1S,2S-(+)-1,2-diaminocyclohexane (0.14 g,1.2 mmol)/1S,2S-(-)-1,2-diphenylethane-1,2-diamine (0.27 g, 1.2 mmol) in dry THF (0.6 mL) was added slowly and the resultant solutions were stirred at room temperature. After completion of the reaction (2 h) checked on TLC, the solvent was removed completely under reduced pressure. The bright yellow solids were extracted with dichloromethane (50 mL), and the organic layer was washed with water (3 ¡Á 50 mL), brine (3 ¡Á 50 mL) and finally dried over anhydrous Na2SO4. After removal of dichloromethane under reduced pressure, the chiral dimeric macrocyclic ligands 3′ and 4′ were purified by silica gel chromatography (100-200 mesh) with a EtOAc-to-Hexane of 3:2.3′: Yield 96%. m.p. 76 C. 1H NMR (500 MHz, CDCl3): delta 1.38 (36H, s),1.67-1.93 (16H, m), 3.32 (4H, m), 3.55 (8H, t, J = 5), 3.61 (16H, t, J = 7), 4.37 (8H, s), 6.97 (4H, s), 7.20 (4H, s), 8.26 (4H, s), 13.86 (4H, br) ppm. 13C NMR (125 MHz, CDCl3): 25.0, 31.0, 34.7, 70.7, 72.2, 74.0, 74.8, 79.0, 119.8, 128.7, 131.2, 138.8, 161.6, 167.0 ppm; FT-IR (KBr): nu 3424, 2934, 2863, 2361, 1628, 1537, 1446, 1384, 1317, 1239, 1098, 940, 868, 785, 671, 563, 420 cm-1. (c = 0.052, CH2Cl2). Anal. Calcd. for C72H104N4O12 C, 71.02; H, 8.61; N, 4.60. Found C, 71.05; H, 8.63; N, 4.62. MALDI-TOF: m/z Calcd. for [C72H104N4O12] 1217.62, Found 1218.19 [M+H].4′: Yield 93%. m.p. 95 C. 1H NMR (200 MHz, CDCl3): delta 1.40 (36H, s), 3.53-3.63 (24H, m), 4.37 (8H, s), 4.71 (4H, s), 6.97 (4H, s), 7.19-7.29 (24H, m), 8.32 (4H, s), 13.78 (4H, br) ppm. 13C NMR (50 MHz, CDCl3): 29.3, 34.8, 69.1, 70.6, 73.1, 80.0, 118.1, 127.6, 128.1, 128.3, 129.8, 137.3, 139.5, 159.9, 166.7 ppm. FT-IR (KBr): nu 3452, 2952, 2865, 2361, 1626, 1446, 1386, 1357, 1320, 1266, 1208, 1100, 1035, 936, 871, 801, 775, 573 cm-1. (c = 0.108, CHCl3). Anal. Calcd. for C88H108N4O12 C, 74.76; H, 7.70; N, 3.96. Found C, 74.75; H, 7.73; N, 3.98. MALDI-TOF: m/z Calcd. for [C88H108N4O12] 1413.82, Found 1414.19 [M+H].

29841-69-8, The synthetic route of 29841-69-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kureshy, Rukhsana I.; Roy, Tamal; Khan, Noor-Ul H.; Abdi, Sayed H.R.; Sadhukhan, Arghya; Bajaj, Hari C.; Journal of Catalysis; vol. 286; (2012); p. 41 – 50;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

78902-09-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.78902-09-7,2-(2,2-Diethoxyethyl)isoindoline-1,3-dione,as a common compound, the synthetic route is as follows.

2-{2-ethoxy-2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]ethyl}-1H-isoindole-1,3(2H)-dione (Compound 42) To 50 ml dichloromethane solution of 2-(2,2-diethoxyethyl)-1H-isoindole-1,3(2H)-dione (6.8 g, 25.8 mmol) under an ice bath was added 2,6-lutidine (9.89 mL, 85 mmol) and TMSOTf (10.3 mL, 56.8 mmol). The reaction stirred under the ice bath for one hour. After which, (9Z,12Z)-octadeca-9,12-dien-1-ol (24.3 mL, 77 mmol) was added in and the reaction was stirred from 0 C. to 20 C. for 16 hours. The reaction was diluted with 200 mL dichloromethane and washed by 100 mL of NaHCO3 solution, water, brine. The organic was dried over Na2SO4, filtrated and purified by silica gel chromatography (0% ethyl acetate/hexane?18% ethyl acetate/hexane) to give title compound (12.1 g). MS 506.5 (M+Na).

The synthetic route of 78902-09-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SIRNA THERAPEUTICS, INC.; Colletti, Steven L.; Deng, Zhengwu James; Stanton, Matthew G.; Wang, Weimin; Hills, Ivory; (47 pag.)US9670487; (2017); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI